Patents by Inventor John Fitzmaurice Valliant

John Fitzmaurice Valliant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Residualizing linkers and uses thereof
    Patent number: 11793895
    Abstract: The present invention relates to conjugates including a residualizing linker, methods for their production, and uses thereof.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: October 24, 2023
    Inventors: John Fitzmaurice Valliant, Eric Steven Burak, Neil G. Cockburn, Alla Darwish, Joel A. Drewry, John R. Forbes, Meiduo Hu, Ryan W. Simms, Karin A. Stephenson, Tao Wu
  • RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY
    Publication number: 20230270895
    Abstract: Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.
    Type: Application
    Filed: August 15, 2022
    Publication date: August 31, 2023
    Inventors: Eric Steven Burak, Julie Metcalf, Natalie Grinshtein, Meiduo Hu, John Fitzmaurice Valliant
  • IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF
    Publication number: 20230052140
    Abstract: The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.
    Type: Application
    Filed: July 28, 2022
    Publication date: February 16, 2023
    Inventors: Eric Steven Burak, John Richard Forbes, Matthew David Burr Moran, Ryan Wayne Simms, John Fitzmaurice Valliant, Alla Darwish
  • Actinium-225 and checkpoint inhibitor combination therapy
    Patent number: 11446401
    Abstract: Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: September 20, 2022
    Assignee: Fusion Pharmaceuticals Inc.
    Inventors: Eric Steven Burak, Julie Metcalf, Natalie Grinshtein, Meiduo Hu, John Fitzmaurice Valliant
  • IGF-1R monoclonal antibodies and uses thereof
    Patent number: 11433148
    Abstract: The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: September 6, 2022
    Assignee: Centre for Probe Development and Commercialization
    Inventors: Eric Steven Burak, John Richard Forbes, Matthew David Burr Moran, Ryan Wayne Simms, John Fitzmaurice Valliant, Alla Darwish
  • RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY
    Publication number: 20220088231
    Abstract: Combination therapies comprising administering radioimmunoconjugates and DNA damage response inhibitors.
    Type: Application
    Filed: December 3, 2019
    Publication date: March 24, 2022
    Inventors: Eric Steven BURAK, John Richard FORBES, Meiduo HU, John Fitzmaurice VALLIANT
  • RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY
    Publication number: 20220088230
    Abstract: Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.
    Type: Application
    Filed: December 3, 2019
    Publication date: March 24, 2022
    Inventors: Eric Steven BURAK, Julie METCALF, Natalie GRINSHTEIN, Meiduo HU, John Fitzmaurice VALLIANT
  • PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF
    Publication number: 20220054664
    Abstract: The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.
    Type: Application
    Filed: November 2, 2021
    Publication date: February 24, 2022
    Inventors: Eric Steven Burak, Stuart James Mahoney, Ryan Wayne Simms, John Fitzmaurice Valliant, Alla Darwish
  • Pharmacokinetic enhancements of bifunctional chelates and uses thereof
    Patent number: 11191854
    Abstract: The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: December 7, 2021
    Assignee: Centre for Probe Development and Commercialization
    Inventors: Eric Steven Burak, Stuart James Mahoney, Ryan Wayne Simms, John Fitzmaurice Valliant, Alla Darwish
  • RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY
    Publication number: 20210290788
    Abstract: Combination therapies comprising administering radioimmunoconjugates and DNA damage response inhibitors.
    Type: Application
    Filed: June 2, 2021
    Publication date: September 23, 2021
    Inventors: Eric Steven Burak, John Richard Forbes, Meiduo Hu, John Fitzmaurice Valliant
  • RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY
    Publication number: 20210290789
    Abstract: Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.
    Type: Application
    Filed: June 2, 2021
    Publication date: September 23, 2021
    Inventors: Eric Steven Burak, Julie Metcalf, Natalie Grinshtein, Meiduo Hu, John Fitzmaurice Valliant
  • RESIDUALIZING LINKERS AND USES THEREOF
    Publication number: 20210060190
    Abstract: The present invention relates to conjugates including a residualizing linker, methods for their production, and uses thereof.
    Type: Application
    Filed: July 24, 2020
    Publication date: March 4, 2021
    Inventors: John Fitzmaurice Valliant, Eric Steven Burak, Neil Grant Cockbum, Alla Darwish, Joe Adamson Drewry, John Richard Forbes, Meiduo Hu, Ryan Wayne Simms, Karin Ann Stephenson, Tao Wu
  • Residualizing linkers and uses thereof
    Patent number: 10758636
    Abstract: The present invention relates to conjugates including a residualizing linker, methods for their production, and uses thereof.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: September 1, 2020
    Assignee: CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION
    Inventors: John Fitzmaurice Valliant, Eric Steven Burak, Neil Grant Cockburn, Alla Darwish, Joel Adamson Drewry, John Richard Forbes, Meiduo Hu, Ryan Wayne Simms, Karin Ann Stephenson, Tao Wu
  • IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF
    Publication number: 20190083662
    Abstract: The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.
    Type: Application
    Filed: May 4, 2018
    Publication date: March 21, 2019
    Inventors: Eric Steven Burak, John Richard Forbes, Matthew David Burr Moran, Ryan Wayne Simms, John Fitzmaurice Valliant
  • PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF
    Publication number: 20190030194
    Abstract: The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.
    Type: Application
    Filed: May 4, 2018
    Publication date: January 31, 2019
    Inventors: Eric Steven Burak, Stuart James Mahoney, Ryan Wayne Simms, John Fitzmaurice Valliant
  • IGF-1R monoclonal antibodies and uses thereof
    Patent number: 10093741
    Abstract: The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: October 9, 2018
    Assignee: Fusion Pharmaceuticals Inc.
    Inventors: Eric Steven Burak, John Richard Forbes, Matthew David Burr Moran, Ryan Wayne Simms, John Fitzmaurice Valliant
  • RESIDUALIZING LINKERS AND USES THEREOF
    Publication number: 20160279272
    Abstract: The present invention relates to conjugates including a residualizing linker, methods for their production, and uses thereof.
    Type: Application
    Filed: November 12, 2014
    Publication date: September 29, 2016
    Inventors: John Fitzmaurice VALLIANT, Eric Steven BURAK, Neil Grant COCKBURN, Alla DARWISH, Joel Adamson DREWRY, John Richard FORBES, Meiduo HU, Ryan Wayne SIMMS, Karin Ann STEPHENSON, Tao WU
  • Tc imaging agents and methods of use
    Patent number: 9125955
    Abstract: An embodiment of the invention comprises method of imaging a target site comprising administrating ligand of Formula I complexed to 99mTc wherein R1 and R2 are independently an alkyl or cycloalkyl; R3 is and alkyl; X is CO or SO2; Y is (CH2)n, C6H4, (OCH2CH2)n(NHCH2CH2)n and (OCH2CH2CH2)n, or a combination thereof; Z is linker group capable of conjugating to a vector; and n is an integer between 0 and 10.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: September 8, 2015
    Assignee: General Electric Company
    Inventors: Bruce Fletcher Johnson, Randall Lee Carter, Michael James Rishel, Mark Christopher Patrick Darey, Tao Wu, Yang Yang, John Fitzmaurice Valliant, Karin Ann Stephenson
  • Biotin stannane for HPLC-free radioiodination
    Patent number: 8927732
    Abstract: The present teachings provide methods that enable the preparation and purification of radioiodinated vectors without the need for HPLC purification, as well as novel precursors which include biotin-like substituents useful in such methods.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: January 6, 2015
    Assignee: General Electric Company
    Inventors: Randall Lee Carter, Bruce Fletcher Johnson, Anup Sood, Michael James Rishel, John Fitzmaurice Valliant, Karin Ann Stephenson, Tao Wu, Yang Yang
  • 99mTc IMAGING AGENTS AND METHODS OF USE
    Publication number: 20140065065
    Abstract: An embodiment of the invention comprises method of imaging a target site comprising administrating ligand of Formula I complexed to 99mTc wherein R1 and R2 are independently an alkyl or cycloalkyl; R3 is and alkyl; X is CO or SO2; Y is (CH2)n, C6H4, (OCH2CH2)n (NHCH2CH2)n and (OCH2CH2CH2)n, or a combination thereof; Z is linker group capable of conjugating to a vector; and n is an integer between 0 and 10.
    Type: Application
    Filed: November 6, 2013
    Publication date: March 6, 2014
    Applicant: GENERAL ELECTRIC COMPANY
    Inventors: Bruce Fletcher Johnson, Randall Lee Carter, Michael James Rishel, Mark Christopher Patrick Darey, Tao Wu, Yang Yang, John Fitzmaurice Valliant, Karin Ann Stephenson